HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone...
TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived...
Sustained Breakthroughs in The Green and Health Business With Approximately HK$4 Billion in cash Recovered from the Successful Privatization of Canvest Environmental ...
SUZHOU, China, Aug. 28, 2025 /PRNewswire/ -- Recently, ECOVACS (603486.SH), a global leader in service robotics, has outlined its environmental, social and governance performance...